pak-2 Antibody

Introduction to PAK2 and PAK2 Antibody

PAK2 (p21-activated kinase 2) is a serine/threonine-protein kinase encoded by the PAK2 gene, functioning as a downstream effector of Rho GTPases Rac1 and Cdc42 . It regulates diverse cellular processes, including cytoskeletal remodeling, apoptosis, and oncogenesis . PAK2 antibodies are immunochemical tools designed to detect and study PAK2 expression, localization, and function in experimental settings. These antibodies are critical for elucidating PAK2’s roles in diseases such as cancer, peripheral neuropathies, and immune disorders .

Role in Peripheral Nerve Myelination

PAK2 is essential for Schwann cell-mediated myelination. Studies using conditional Pak2 knockout mice revealed severe hypomyelination and reduced nerve conduction velocity, linking PAK2 to Rac1/Cdc42 signaling in peripheral nerve development .

Oncogenic Signaling in Cancer

• Head and Neck Cancer (HNC): PAK2 drives the PAK2–c-Myc–PKM2 axis, promoting glycolysis, proliferation, and chemoresistance. Depletion of PAK2 reduces migration, invasion, and colony formation in HNC cells .

• Breast Cancer: PAK2 and PAK1 exhibit non-redundant roles in tumor cell invasion. PAK2 depletion increases RhoA activity, impairing focal adhesion maturation .

Immune System Regulation

• T-Cell Development: PAK2 is critical for thymocyte survival, TCR signaling, and actin cytoskeleton remodeling. Pak2 deficiency in mice causes T-cell lymphopenia and blocks β-selection during thymocyte maturation .

• Mechanotransduction: PAK2 links mechanical force to cell survival by interacting with AMPK and Abl kinases, preventing apoptosis under tension .

Table 2: PAK2 Protein Attributes

Functional Domains:

• Kinase Domain: Mediates phosphorylation of substrates like BAD (apoptosis regulation) .

• Cdc42/Rac Binding Domain: Facilitates GTPase-dependent activation .

Future Directions and Therapeutic Potential

PAK2 antibodies are pivotal for:

• Biomarker Development: Correlating PAK2 expression with cancer prognosis .

• Drug Discovery: Targeting PAK2–c-Myc–PKM2 in HNC or PAK2–AMPK–Abl in mechanotransduction pathways .

• Neuropathy Treatments: Modulating PAK2 activity to enhance myelination in peripheral nerve disorders .